Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 13Terminated 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Cyclophosphamide 47aldesleukin 30fludarabine phosphate 26fludarabine 24Carboplatin 18Rituximab 16Interleukin-2 16Cisplatin 16Bevacizumab 162,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 16Radiotherapy 15Paclitaxel 15Magnetic Resonance Spectroscopy 14Bortezomib 14Filgrastim 13Doxorubicin 13Oxaliplatin 12Erlotinib Hydrochloride 12Trastuzumab 11Leucovorin 11Etoposide 11Biopsy 11Taxes 10Radiation 10Fluorouracil 10alvocidib 9Specimen Handling 9Sorafenib 9Docetaxel 9Dexamethasone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × NIH × PROSTVAC × Clear all
NCT01145508 2017-09-19

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

NCT00005039 2013-01-24

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

National Cancer Institute (NCI)

Phase 2 Terminated
86 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡